NEW YORK – The World Health Organization announced on Friday that its Medicines Patent Pool has sublicensed technology for rapid diagnostic testing to Nigeria’s Codix Bio.

The money will support the development of the firm's PidPort system for storage, viewing, sharing, and analysis of digital images of pathology slides.

The firm filed for Chapter 11 protection on Thursday and is seeking to sell its assets after facing turmoil in recent years.

Kuppusamy noted that Quest does offer testing, and advanced diagnostic testing in particular, through its Global Diagnostics ...

April's clearances included respiratory disease assays, a Gram-negative infection test, and assays to aid the diagnosis and monitoring of thyroid disease.

The firm has been engaging with payors and insurance plan administrators following the release of results from its study on the use of the firm's PreTRM Test.

The company has received a commitment of up to $12.5 million in a multi-draw DIP financing facility to provide funding during the proceeding.

NEW YORK — Exagen, a developer of autoimmune testing technologies, said on Thursday it expects to raise around $17.6 million through a public offering of its common stock.

Congress has passed delays to PAMA implementation, but such a pause could be less likely this year, warn industry stakeholders.

The firm reported that its total revenues jumped 9 percent in Q2, but it lowered the low end of its EPS guidance to account for the uncertainty of tariffs and other trade barriers.

The offering consisted of 10,156,250 shares of common stock or pre-funded warrants, together with warrants to purchase up to 15,234,375 shares of common stock.

The firm reported that its total revenues jumped 9 percent in Q2, but it lowered the low end of its EPS guidance to account for the uncertainty of tariffs and other trade barriers.